OBJECTIVE: The aim of this study was to determine whether MSM using preexposure prophylaxis (PrEP) are at a higher risk of bacterial sexually transmitted infections (STIs) than MSM not using PrEP. DESIGN: Secondary analysis of longitudinal STI data obtained from MSM attending an STD Clinic in Seattle, Washington, USA, October 2011-September 2017. METHODS: We identified patients obtaining PrEP through the STD Clinic, and used propensity score matching to select a historical group of similar patients not using PrEP for comparison. We linked patient data with STI surveillance data to compare the incidence of chlamydia, gonorrhoea and early syphilis, and time to first symptomatic STI among PrEP users and nonusers. RESULTS: Three hundred and sixty-five PrEP users who picked up prescriptions and returned for follow-up and 730 propensity score matched nonusers were included in the analysis. Adjusted incidence rate ratios (aIRRs) for chlamydia, gonorrhoea and early syphilis were 3.2 [95% confidence interval (95% CI): 1.9-5.3], 2.8 (95% CI: 1.7-4.6) and 2.9 (95% CI: 1.5 - 5.6), respectively, comparing PrEP users to nonusers. Time to first symptomatic STI was shorter among PrEP users (120 days, 95% CI: 77 - 171) than among nonusers (185 days, 95% CI: 163-256). CONCLUSION: Among MSM on PrEP, we observed a higher incidence of STIs and faster time to first symptomatic STI than MSM not using PrEP. PrEP may be a contributing factor in increasing STI rates among MSM.
OBJECTIVE: The aim of this study was to determine whether MSM using preexposure prophylaxis (PrEP) are at a higher risk of bacterial sexually transmitted infections (STIs) than MSM not using PrEP. DESIGN: Secondary analysis of longitudinal STI data obtained from MSM attending an STD Clinic in Seattle, Washington, USA, October 2011-September 2017. METHODS: We identified patients obtaining PrEP through the STD Clinic, and used propensity score matching to select a historical group of similar patients not using PrEP for comparison. We linked patient data with STI surveillance data to compare the incidence of chlamydia, gonorrhoea and early syphilis, and time to first symptomatic STI among PrEP users and nonusers. RESULTS: Three hundred and sixty-five PrEP users who picked up prescriptions and returned for follow-up and 730 propensity score matched nonusers were included in the analysis. Adjusted incidence rate ratios (aIRRs) for chlamydia, gonorrhoea and early syphilis were 3.2 [95% confidence interval (95% CI): 1.9-5.3], 2.8 (95% CI: 1.7-4.6) and 2.9 (95% CI: 1.5 - 5.6), respectively, comparing PrEP users to nonusers. Time to first symptomatic STI was shorter among PrEP users (120 days, 95% CI: 77 - 171) than among nonusers (185 days, 95% CI: 163-256). CONCLUSION: Among MSM on PrEP, we observed a higher incidence of STIs and faster time to first symptomatic STI than MSM not using PrEP. PrEP may be a contributing factor in increasing STI rates among MSM.
Authors: Robert M Grant; Javier R Lama; Peter L Anderson; Vanessa McMahan; Albert Y Liu; Lorena Vargas; Pedro Goicochea; Martín Casapía; Juan Vicente Guanira-Carranza; Maria E Ramirez-Cardich; Orlando Montoya-Herrera; Telmo Fernández; Valdilea G Veloso; Susan P Buchbinder; Suwat Chariyalertsak; Mauro Schechter; Linda-Gail Bekker; Kenneth H Mayer; Esper Georges Kallás; K Rivet Amico; Kathleen Mulligan; Lane R Bushman; Robert J Hance; Carmela Ganoza; Patricia Defechereux; Brian Postle; Furong Wang; J Jeff McConnell; Jia-Hua Zheng; Jeanny Lee; James F Rooney; Howard S Jaffe; Ana I Martinez; David N Burns; David V Glidden Journal: N Engl J Med Date: 2010-11-23 Impact factor: 91.245
Authors: Robert M Grant; Peter L Anderson; Vanessa McMahan; Albert Liu; K Rivet Amico; Megha Mehrotra; Sybil Hosek; Carlos Mosquera; Martin Casapia; Orlando Montoya; Susan Buchbinder; Valdilea G Veloso; Kenneth Mayer; Suwat Chariyalertsak; Linda-Gail Bekker; Esper G Kallas; Mauro Schechter; Juan Guanira; Lane Bushman; David N Burns; James F Rooney; David V Glidden Journal: Lancet Infect Dis Date: 2014-07-22 Impact factor: 25.071
Authors: Luxi Lal; Jennifer Audsley; Dean A Murphy; Christopher K Fairley; Mark Stoove; Norm Roth; Richard Moore; Ban K Tee; Nalagafiar Puratmaja; Peter L Anderson; David Leslie; Robert M Grant; John De Wit; Edwina Wright Journal: AIDS Date: 2017-07-31 Impact factor: 4.177
Authors: Michalina A Montaño; Julia C Dombrowski; Sayan Dasgupta; Matthew R Golden; Ann Duerr; Lisa E Manhart; Lindley A Barbee; Christine M Khosropour Journal: AIDS Behav Date: 2019-02
Authors: Michael E Newcomb; Kevin Moran; Brian A Feinstein; Emily Forscher; Brian Mustanski Journal: J Acquir Immune Defic Syndr Date: 2018-04-01 Impact factor: 3.731
Authors: Albert Y Liu; Stephanie E Cohen; Eric Vittinghoff; Peter L Anderson; Susanne Doblecki-Lewis; Oliver Bacon; Wairimu Chege; Brian S Postle; Tim Matheson; K Rivet Amico; Teri Liegler; M Keith Rawlings; Nikole Trainor; Robert Wilder Blue; Yannine Estrada; Megan E Coleman; Gabriel Cardenas; Daniel J Feaster; Robert Grant; Susan S Philip; Richard Elion; Susan Buchbinder; Michael A Kolber Journal: JAMA Intern Med Date: 2016-01 Impact factor: 21.873
Authors: Jonathan E Volk; Julia L Marcus; Tony Phengrasamy; Derek Blechinger; Dong Phuong Nguyen; Stephen Follansbee; C Bradley Hare Journal: Clin Infect Dis Date: 2015-09-01 Impact factor: 9.079
Authors: Elske Hoornenborg; Liza Coyer; Anna van Laarhoven; Roel Achterbergh; Henry de Vries; Maria Prins; Maarten Schim van der Loeff Journal: AIDS Date: 2018-07-17 Impact factor: 4.177